Limited Submission Funding Opportunities – updated 2/15/19

Please be aware that any grant that brings in less than 15% in indirect costs (IDC) will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 15% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of $50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.

This policy is only effective for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.

For further questions, please contact ECOR at ecor@mgh.harvard.edu

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

Process
Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to ecor@mgh.harvard.edu. In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:
1. Name of the Principal Investigator with appropriate contact information
2. A descriptive title of the potential application
3. Brief description of the project
4. Brief description of why you specifically should be selected to receive institutional nomination for this award

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at ecor@mgh.harvard.edu.

CURRENT OPPORTUNITIES

1. The KUH/NIDDK Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 Independent Clinical Trial Not Allowed)
   MGH LOI Deadline: 2/18/19
   NIH LOI Deadline: 3/10/19
   NIH Deadline: 4/10/19

   The purpose of the KUH/NIDDK Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to recruit exceptional graduate students who are recognized by their institutions for their high potential and to incentivize them to pursue a Kidney, Urologic or Hematologic (K, U, or H) postdoctoral position that ultimately positions them to become independent K, U, or H researchers. This two-phase award will facilitate completion of the doctoral dissertation and stabilize the transition of highly talented Ph.D
Limited Submission Funding Opportunities – updated 2/15/19

candidates from a variety of fields, including, but not limited to, engineering, statistics, data science, imaging, biochemistry and genetics into strong postdoctoral appointments that are focused on K, U, or H research. It is anticipated that successful completion of this phased award will make the individual highly competitive for a subsequent NIDDK award (e.g., K99/R00, R01). Opportunities for career development activities relevant to their long-term career goals of becoming independent researchers will be provided. Graduate students who are already involved in K, U, or H research are encouraged to apply for the NIDDK F31 (PA-18-671).

This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

2. Data Coordinating Center for the Advanced Clinical Trials Consortium to Test Artificial Pancreas Device Systems (U24 Clinical Trial Not Allowed)
MGH LOI Deadline: 2/18/19
NIH LOI Deadline: 3/10/19
NIH Deadline: 4/10/19

This Funding Opportunity Announcement (FOA) invites applications for a Data Coordinating Center (DCC) that will support the Advanced Clinical Trials to test Artificial Pancreas device systems. The applicant must have experience serving as the DCC for studies on complex, clinical conditions including the testing of closed loop platforms for diabetes control. The DCC will provide overall project coordination, administration, quality control, data management, and biostatistical support.

3. Botanical Dietary Supplements Research Centers (BDSRC) (U19 Clinical Trial Optional)
MGH LOI Deadline: 2/19/19
NIH LOI Deadline: 3/15/19
NIH Deadline: 4/15/19

This funding opportunity announcement (FOA), for one component of the NIH Consortium for Advancing Research on Botanicals and other Natural Products (CARBON) Program, represents an evolution of the previous Botanical Dietary Supplements Research Centers FOA, RFA OD 14-001. The goal of the consortium is to advance methodology for, and conduct research on, complex natural products. This Botanical Dietary Supplements Research Centers (BDSRC) component of the CARBON will support transdisciplinary collaborations focused on producing the most critical data to inform the optimal design of future clinical trials of orally consumed, complex botanical dietary supplements for which there are rigorous but not definitive preliminary data. The preliminary data provided by responsive applications must support a reproducible, physiologically and mechanistically plausible, and statistically and clinically significant effect on, or relevant to, human biological or cognitive/behavioral, objectively measured resilience. Applications in which a purified phytochemical is the main focus will be considered nonresponsive. Achievement of the BDSRC Specific Aims is expected to contribute critical information for the design of optimally informative clinical trials. Results from the BDSRC might, for example, be targeted to inform decisions related to specific trial design, product formulation(s), doses, timing, eligibility
4. Environmental Health Sciences Core Centers (EHSCC) (P30 Clinical Trial Optional)
   MGH LOI Deadline: 2/20/19
   NIH LOI Deadline: 3/17/19
   NIH Deadline: 4/17/19

This Funding Opportunity Announcement (FOA) invites grant applications for Environmental Health Sciences Core Centers (EHS CC). As intellectual hubs for environmental health research, the EHS CC is expected to be the thought leaders for the field and advance the goals of the NIEHS Strategic Plan (http://www.niehs.nih.gov/about/strategicplan/). The Core Centers provide critical research infrastructure, shared facilities, services and/or resources, to groups of investigators conducting environmental health sciences research. An EHS CC enables researchers to conduct their independently-funded individual and/or collaborative research projects more efficiently and/or more effectively. The broad overall goal of an EHS CC is to identify and capitalize on emerging issues that advance improving the understanding of the relationships among environmental exposures, human biology, and disease. The EHS CC supports community engagement and translational research as key approaches to improving public health.

5. Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed)
   MGH LOI Deadline: 2/28/19
   NIH LOI Deadline: 3/25/19
   NIH Deadline: 4/25/19

This Funding Opportunity Announcement (FOA) invites applications for P30 Alzheimer's Disease Research Centers. NIA-designated Alzheimer's Disease Research Centers (ADRCs) serve as major sources of discovery into the nature of Alzheimer’s disease (AD) and related dementias and into the development of more effective approaches to prevention, diagnosis, care, and therapy. They contribute significantly to the development of shared resources that support dementia-relevant research, and they collaborate and coordinate their research efforts with other NIH-funded programs and investigators.

   http://breastcanceralliance.org/how-to-apply
   MGH LOI Deadline: 3/05/19
   Sponsor LOI Deadline: 4/05/19
   Sponsor Deadline: 7/19/19

The Breast Cancer Alliance invites clinical doctors and research scientists at any stage of their careers whose primary focus is breast cancer to apply for an Exceptional Project Grant. This award recognizes creative, unique and innovative research. The term of the Exceptional Project Grant is one year and provides salary support and project costs of $100,000. Administrative costs, which are included in the $100,000 award, must be limited to 8% of grant funds. Prior to submission of a formal grant proposal, the BCA requires a one-page Letter of Intent (LOI) and a separate CV.
Limited Submission Funding Opportunities – *updated 2/15/19*

Please be sure to include the following information in your letter:

1. Applicant's name, job title, and the applicant's contact information
2. State the project title and hypothesis, outline the research aim(s) and methods
3. A brief discussion of the project's potential impact

In the event that there are more than 2 applicants, the LOIs will be used to assess if a review and selection process will be needed. ECOR will notify all interested applicants by March 22, 2019.

7. **The Experimental Therapeutics Clinical Trials Network (UM1 Clinical Trial Required)**
   
   MGH LOI Deadline: 3/25/19
   NIH LOI Deadline: 4/22/19
   NIH Deadline: 5/22/19

   The purpose of this Funding Opportunity Announcement (FOA) issued by The National Cancer Institute (NCI) is to continue support for the Experimental Therapeutics Clinical Trials Network (ETCTN) for the efficient and comprehensive conduct of early phase clinical trials of NCI Investigational New Drug (IND) agents. The ETCTN is designed to assure the availability of investigators and programs with expertise in early drug development and translational research for this purpose. This FOA solicits UM1 cooperative agreement applications from appropriate multidisciplinary groups that can assemble an appropriate infrastructure and conduct phase 0, phase 1, phase 2, pilot and other experimental therapeutics clinical trials involving agents for which the NCI’s Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP) received IND status. The FOA is open to any qualified applicant regardless of whether they have been previously associated with the ETCTN.

8. **The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Laboratories (U24 Clinical Trial Not Allowed)**
   
   MGH LOI Deadline: 3/25/19
   NIH LOI Deadline: 4/22/19
   NIH Deadline: 5/22/19

   The purpose of this Funding Opportunity Announcement (FOA) issued by The National Cancer Institute (NCI) is to create Pharmacokinetics Resource Laboratories (PK Laboratories) that will support the Experimental Therapeutics Clinical Trials Network (ETCTN). The PK Laboratories will be expected to organize specimen collection and subsequent analysis of pharmacokinetic endpoints, drug-drug interactions, cytochromes P450 (CYP) interactions, and food effects in ETCTN studies of NCI Investigational New Drug (IND) agents. The overarching goal of the ETCTN PK Laboratories is to advance the clinical development of NCI-IND agents through achieving comprehensive understanding of pharmacokinetic behavior of these agents studied in ETCTN protocols. The ETCTN Pharmacokinetic Resource Laboratories will assure the availability of physicians, clinical pharmacologists, nurses and scientists who have the appropriate expertise in pharmacokinetic studies for early drug development and translational research. This FOA seeks U24 cooperative agreement applications from multidisciplinary groups that will conduct all pharmacokinetic studies for ETCTN early phase clinical trials filed to the IND applications in NCI’s Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP).

9. **NIDCR Mentoring Network to Support a Diverse Dental, Oral and Craniofacial Research Workforce (UE5 Clinical Trial Not Allowed)**
Limited Submission Funding Opportunities – updated 2/15/19


MGH LOI Deadline: 3/30/19
NIH LOI Deadline: 4/30/19
NIH Deadline: 5/30/19

The NIH Research Education Projects Cooperative Agreements Program (UE5) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDCR UE5 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce. The major goal of this UE5 program is to establish a mentoring network that will facilitate a diverse pool of early career investigators, including those from groups identified as underrepresented (see NOT-OD-18-210), to advance their research careers and/or transition to the next career stage and to develop a high quality independently funded research program. This FOA invites applications from senior faculty, experienced mentors and experienced researchers to develop and direct a mentoring network for eligible early career investigators (post doctorates and junior faculty) to foster a career trajectory towards independent dental, oral and craniofacial health research. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Mentoring Activities and Courses for Skills Development. Proposed programs are expected to contribute to the development of a skilled cadre of investigators in requisite scientific research areas to advance the objectives of the NIDCR Strategic Plan.

10. Graduate Research Training Initiative for Student Enhancement (G-RISE) (T32)

MGH LOI Deadline: 4/01/19
NIH Deadline: 5/21/19

The goal of the Graduate Research Training Initiative for Student Enhancement (G-RISE) program is to develop a diverse pool of scientists earning a Ph.D., who have the skills to successfully transition into careers in the biomedical research workforce. This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-based approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. This program is limited to applications from training programs at research-active institutions (i.e., those with an average of NIH Research Project Grant funding less than $7.5 million total costs over the last 3 fiscal years). This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

11. Institutional Development Award (IDeA) Program Infrastructure for Clinical and Translational Research (IDeA-CTR) (U54 Clinical Trial Optional) – NEW!

MGH LOI Deadline: 7/15/19
NIH LOI Deadline: 9/02/19
NIH Deadline: 10/02/19

The purpose of this Funding Opportunity Announcement (FOA) is to support the development of infrastructure and other resources required for the conduct of Clinical and Translational Research (CTR) in IDeA-eligible states. IDeA-CTR Centers are expected to provide added value to the biomedical research efforts in the participating institutions through support of activities that cannot easily be provided through standard research grant awards. The proposed activities will provide the infrastructure and
resources that will enhance the competitiveness of the investigators to obtain additional funding for clinical and translational research.

Applicants must establish a statewide network of collaborating and partnering institutions/organizations. Other institutions/organizations outside the state may be included if forming a network of wider reach. Since only one award will be made per IDeA-eligible state, only one application should be submitted per state.